Prospective Collection of Clinical Data and Human Body Material (HBM) of Cutaneous Melanoma, Non Melanoma Patients and Healthy Controls. Biobank Huidkanker

Prospective Collection of Clinical Data and Human Body Material (HBM): Blood (Serum, Plasma, DNA) and Tissue of Cutaneous Melanoma, Non Melanoma Patients and Healthy Controls. Biobank Huidkanker

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07266142

Enrollment

7500

Registered

2025-12-05

Start date

2025-11-17

Completion date

2051-01-01

Last updated

2026-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin Cancer Melanoma, Skin Cancer, Non-Melanoma

Keywords

Prospective Collection, Skin Cancer, Human Body Material

Brief summary

The goal of this clinical trial is to set up a prospective, fit-for-purpose collection of human body material (HBM)-blood (serum, plasma, DNA) and tissue-and standardized clinical data of patients with cutaneous melanoma, non-melanoma skin cancer and healthy controls. The main questions it aims to answer are: * To create a biobank with samples of human body material (HBM): blood (serum/plasma/DNA) and tissue and clinical data of patients with cutaneous melanoma, non-melanoma and helathy controls. * To support future research questions (after specific approval of the Ethics Committee) by using the biobank (through satellite protocols). If there is a comparison group: Not applicable (umbrella protocol for collection only). Participants will: * Share demographics, medical and surgical history, risk factors. * Complete Cancer Worry Scale questionnaire. * Provide biological samples: * Blood samples (serum, plasma, DNA). * Tissue samples (residual tissue or additional biopsy if consented).

Interventions

OTHERCollection of Human Body Material and Clinical Data

Blood sampling (serum, plasma, DNA) Tissue sampling (additional biopsy if consented) Completion of Cancer Worry Scale questionnaire

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures * Adult subjects (\>18 years of age) at time of enrolment. * Subjects diagnosed with cutaneous melanoma, Non-melanoma skin cancer or healthy controls. * Adult subjects able and willing to provide informed consent.

Exclusion criteria

* Subjects unable or not willing to provide informed consent. * Pregnancy (or willing to become pregnant) is NOT an

Design outcomes

Primary

Measure	Time frame	Description
Establishment of a biobank of human body material (HBM) and clinical data	Baseline (diagnosis and informed consent) through study completion, approximately 10 years.	Successful prospective collection and long-term storage of blood (serum, plasma, DNA), tissue samples, and associated clinical data from patients with cutaneous melanoma, non-melanoma skin cancer and healthy controls.

Secondary

Measure	Time frame	Description
Availability of biobank resources for future research	Baseline (diagnosis and informed consent) through study completion, approximately 10 years.	Number of approved satellite protocols using biobank samples and data for translational research.

Countries

Belgium

Contacts

CONTACTAnnemiek Leeman, Prof. Dr.

annemiek.leeman@uzleuven.be0032 016337950

CONTACTSofie Van Kelst, BSc

sofie.vankelst@kuleuven.be0032 016337864

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 13, 2026